Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 杨明明教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1007/s11912-015-0486-5 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/1WOS source URL
其它资讯
摘要Nausea and vomiting are common in cancer patients. The most common cause of nausea and vomiting is the administration of cytotoxic chemotherapy. Apart from chemotherapy-induced nausea and vomiting (CINV), biological agents may also cause these symptoms. In this review, discussion will be focused on management of nausea and vomiting due to antineoplastic therapies. The cornerstone of effective management of nausea and vomiting secondary to these antineoplastic drugs is the prevention with the use of appropriate guideline-directed combination antiemetic regimen. Type 3 serotonin receptor antagonists (5HT3RAs), neurokinin-http://aims.cuhk.edu.hk/converis/portal/Publication/1 receptor antagonists (NKhttp://aims.cuhk.edu.hk/converis/portal/Publication/1RAs), and dexamethasone are the backbone antiemetic drugs. In recent years, newer drugs and preparations have been introduced for clinical use and include second-generation 5HT3RA, palonosetron; granisetron transdermal patch; the recently introduced NKhttp://aims.cuhk.edu.hk/converis/portal/Publication/1RA rolapitant; and the novel oral combined drug NEPA (netupitant plus palonosetron); and last but not least, the atypical antipsychotic olanzapine.
着者Lau TKH, Yip CHW, Yeo W
期刊名称CURRENT ONCOLOGY REPORTS
出版年份20http://aims.cuhk.edu.hk/converis/portal/Publication/16
月份http://aims.cuhk.edu.hk/converis/portal/Publication/1
日期http://aims.cuhk.edu.hk/converis/portal/Publication/1
卷号http://aims.cuhk.edu.hk/converis/portal/Publication/18
期次http://aims.cuhk.edu.hk/converis/portal/Publication/1
出版社SPRINGER
国际标準期刊号http://aims.cuhk.edu.hk/converis/portal/Publication/1523-3790
电子国际标準期刊号http://aims.cuhk.edu.hk/converis/portal/Publication/1534-6269
语言英式英语
关键词Antiemetics; Chemotherapy-induced nausea and vomiting; Emetogenic potential
Web of Science 学科类别Oncology
